Inspire Announces Webcasts of Presentations at Needham Healthcare Conference and Jefferies Life Sciences Conference
(Durham, N.C.) Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) announced today that Adrian Adams, President and CEO, and Thomas R. Staab, II, Executive Vice President and CFO, will present at the Needham & Company 9th Annual Healthcare Conference Thursday, June 10 at 2:40 pm ET and the Jefferies 2010 Global Life Sciences Conference Friday, June 11 at 9:00 am ET in New York City.
The webcasts of the presentations will be available on Inspire’s web site at www.inspirepharm.com. An archived version of the webcast presentations will also be available through this link for a limited time following the conference.
Inspire is a biopharmaceutical company focused on researching, developing and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. Inspire’s goal is to build and commercialize a sustainable portfolio of innovative new products based on its technical, scientific and commercial expertise. The most advanced compounds in Inspire’s clinical pipeline are denufosol tetrasodium for cystic fibrosis and PROLACRIA™ (diquafosol tetrasodium ophthalmic solution) 2% for dry eye, which are both in Phase 3 development, and AZASITE® (azithromycin ophthalmic solution) 1% for blepharitis, which is in Phase 2 development. Inspire receives revenues related to the promotion of AZASITE for bacterial conjunctivitis, the co-promotion of ELESTAT® (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% for dry eye. For more information, visit www.inspirepharm.com.

